Amount Raised
$200 Million
Round Type
Debt Financing
Investors
Description
On November 6, 2026, Atea Pharmaceuticals, Inc. entered into a Loan and Security Agreement providing for term loans totaling up to $200 million. The initial draw of $65 million is aimed to support the development of its antiviral therapy. Additional tranches are contingent on specific milestones related to ongoing clinical trials
Who else raised in Biotechnology around the same time
Companies in the same sectors as Atea Pharmaceuticals, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Helios raised $2.3M (Seed) on November 21, 2026.
- DawaDose raised an undisclosed amount (Seed) on November 19, 2026.
- Xellar Biosystems raised an undisclosed amount on November 19, 2026.
- MetaIntelli Tech raised $45M (Pre-Series A) on November 19, 2026.
- MegaRobo raised $200M on November 19, 2026.
- Vitri Vax raised $87M (Series C) on November 18, 2026.
Who to call at Atea Pharmaceuticals, Inc., and when
A new round usually means Atea Pharmaceuticals, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Atea Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atea Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atea Pharmaceuticals, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atea Pharmaceuticals, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Atea Pharmaceuticals, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.